Cullinan Oncology Completes $131.2 Million Series C Financing
CAMBRIDGE, Mass., December 17, 2020 – Cullinan Oncology, LLC, a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients, announced today the closing of an oversubscribed $131.2 million Series C financing. The financing was led by Foresite Capital with participation from additional new investors: Boxer Capital of Tavistock Group; Eventide Asset Management; Nextech Invest; OrbiMed; Venrock Healthcare Capital Partners; Rock Springs Capital; BVF Partners, L.P.; and Logos Capital. Existing investors, including MPM Capital, F2 Ventures, Cowen Healthcare Investments, The Baupost Group, Schooner Capital, as well as other institutions and individuals, also participated in the round.
“We appreciate the confidence of both our existing as well as new investors in our team and portfolio of assets.” stated Owen Hughes, Cullinan’s CEO.
SVB Leerink is acting as exclusive placement agent to the company in connection with the private placement.
About Cullinan Oncology LLC
Cullinan Oncology was formed to develop a diversified portfolio of single asset oncology opportunities through both internal and external means and to do so in a unique, cost-efficient model that leverages a central management team and shared services model to drive speed and efficiency. For more information, visit www.cullinanoncology.com.
About Foresite Capital
Foresite Capital funds visionary healthcare entrepreneurs. With approximately $3 billion in assets under management, Foresite Capital has a team of clinical scientists, engineers, analysts and partners who support and guide companies at all stages of their life cycles. The firm is headquartered in San Francisco. For more information visit www.foresitecapital.com.